REGN vs. SYK: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at REGN and SYK, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
| Symbol | REGN | SYK |
|---|---|---|
| Company Name | Regeneron Pharmaceuticals, Inc. | Stryker Corporation |
| Country | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Biotechnology | Health Care Equipment & Supplies |
| Market Capitalization | 62.21 billion USD | 150.30 billion USD |
| Exchange | NasdaqGS | NYSE |
| Listing Date | April 2, 1991 | March 17, 1980 |
| Security Type | Common Stock | Common Stock |
Historical Performance
This chart compares the performance of REGN and SYK by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | REGN | SYK |
|---|---|---|
| 5-Day Price Return | -1.87% | 2.16% |
| 13-Week Price Return | -2.70% | 2.44% |
| 26-Week Price Return | -16.19% | 2.71% |
| 52-Week Price Return | -51.06% | 10.97% |
| Month-to-Date Return | 7.61% | 0.11% |
| Year-to-Date Return | -17.60% | 9.19% |
| 10-Day Avg. Volume | 1.06M | 1.17M |
| 3-Month Avg. Volume | 1.21M | 1.27M |
| 3-Month Volatility | 46.69% | 17.00% |
| Beta | 0.32 | 0.97 |
Profitability
Return on Equity (TTM)
REGN
15.11%
Biotechnology Industry
- Max
- 77.14%
- Q3
- 10.76%
- Median
- -20.08%
- Q1
- -42.71%
- Min
- -119.20%
In the upper quartile for the Biotechnology industry, REGN’s Return on Equity of 15.11% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.
SYK
14.08%
Health Care Equipment & Supplies Industry
- Max
- 34.53%
- Q3
- 19.38%
- Median
- 9.52%
- Q1
- 4.86%
- Min
- -7.58%
SYK’s Return on Equity of 14.08% is on par with the norm for the Health Care Equipment & Supplies industry, indicating its profitability relative to shareholder equity is typical for the sector.
Net Profit Margin (TTM)
REGN
31.37%
Biotechnology Industry
- Max
- 59.44%
- Q3
- 16.21%
- Median
- -11.49%
- Q1
- -167.42%
- Min
- -409.07%
A Net Profit Margin of 31.37% places REGN in the upper quartile for the Biotechnology industry, signifying strong profitability and more effective cost management than most of its peers.
SYK
12.25%
Health Care Equipment & Supplies Industry
- Max
- 23.34%
- Q3
- 13.06%
- Median
- 9.53%
- Q1
- 5.96%
- Min
- -3.87%
SYK’s Net Profit Margin of 12.25% is aligned with the median group of its peers in the Health Care Equipment & Supplies industry. This indicates its ability to convert revenue into profit is typical for the sector.
Operating Profit Margin (TTM)
REGN
27.02%
Biotechnology Industry
- Max
- 60.62%
- Q3
- 20.76%
- Median
- -12.41%
- Q1
- -181.14%
- Min
- -482.02%
An Operating Profit Margin of 27.02% places REGN in the upper quartile for the Biotechnology industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
SYK
15.18%
Health Care Equipment & Supplies Industry
- Max
- 29.44%
- Q3
- 17.80%
- Median
- 13.95%
- Q1
- 8.73%
- Min
- -3.56%
SYK’s Operating Profit Margin of 15.18% is around the midpoint for the Health Care Equipment & Supplies industry, indicating that its efficiency in managing core business operations is typical for the sector.
Profitability at a Glance
| Symbol | REGN | SYK |
|---|---|---|
| Return on Equity (TTM) | 15.11% | 14.08% |
| Return on Assets (TTM) | 11.81% | 6.52% |
| Net Profit Margin (TTM) | 31.37% | 12.25% |
| Operating Profit Margin (TTM) | 27.02% | 15.18% |
| Gross Profit Margin (TTM) | 86.46% | 64.62% |
Financial Strength
Current Ratio (MRQ)
REGN
4.60
Biotechnology Industry
- Max
- 19.31
- Q3
- 9.38
- Median
- 4.54
- Q1
- 2.45
- Min
- 0.76
REGN’s Current Ratio of 4.60 aligns with the median group of the Biotechnology industry, indicating that its short-term liquidity is in line with its sector peers.
SYK
1.78
Health Care Equipment & Supplies Industry
- Max
- 4.90
- Q3
- 3.05
- Median
- 2.14
- Q1
- 1.49
- Min
- 0.86
SYK’s Current Ratio of 1.78 aligns with the median group of the Health Care Equipment & Supplies industry, indicating that its short-term liquidity is in line with its sector peers.
Debt-to-Equity Ratio (MRQ)
REGN
0.09
Biotechnology Industry
- Max
- 1.35
- Q3
- 0.64
- Median
- 0.09
- Q1
- 0.00
- Min
- 0.00
REGN’s Debt-to-Equity Ratio of 0.09 is typical for the Biotechnology industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
SYK
0.70
Health Care Equipment & Supplies Industry
- Max
- 1.49
- Q3
- 0.71
- Median
- 0.45
- Q1
- 0.14
- Min
- 0.00
SYK’s Debt-to-Equity Ratio of 0.70 is typical for the Health Care Equipment & Supplies industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
Interest Coverage Ratio (TTM)
REGN
243.95
Biotechnology Industry
- Max
- 72.37
- Q3
- 1.91
- Median
- -7.81
- Q1
- -63.90
- Min
- -153.80
With an Interest Coverage Ratio of 243.95, REGN demonstrates a superior capacity to service its debt, placing it well above the typical range for the Biotechnology industry. This stems from either robust earnings or a conservative debt load.
SYK
14.59
Health Care Equipment & Supplies Industry
- Max
- 58.29
- Q3
- 25.56
- Median
- 9.06
- Q1
- 3.60
- Min
- -28.92
SYK’s Interest Coverage Ratio of 14.59 is positioned comfortably within the norm for the Health Care Equipment & Supplies industry, indicating a standard and healthy capacity to cover its interest payments.
Financial Strength at a Glance
| Symbol | REGN | SYK |
|---|---|---|
| Current Ratio (MRQ) | 4.60 | 1.78 |
| Quick Ratio (MRQ) | 3.78 | 0.88 |
| Debt-to-Equity Ratio (MRQ) | 0.09 | 0.70 |
| Interest Coverage Ratio (TTM) | 243.95 | 14.59 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
REGN
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
REGN currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
SYK
0.83%
Health Care Equipment & Supplies Industry
- Max
- 4.05%
- Q3
- 1.76%
- Median
- 0.71%
- Q1
- 0.00%
- Min
- 0.00%
SYK’s Dividend Yield of 0.83% is consistent with its peers in the Health Care Equipment & Supplies industry, providing a dividend return that is standard for its sector.
Dividend Payout Ratio (TTM)
REGN
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
REGN has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
SYK
42.87%
Health Care Equipment & Supplies Industry
- Max
- 160.00%
- Q3
- 72.47%
- Median
- 27.49%
- Q1
- 0.00%
- Min
- 0.00%
SYK’s Dividend Payout Ratio of 42.87% is within the typical range for the Health Care Equipment & Supplies industry, suggesting a balanced approach between shareholder payouts and company reinvestment.
Dividend at a Glance
| Symbol | REGN | SYK |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.83% |
| Dividend Payout Ratio (TTM) | 0.00% | 42.87% |
Valuation
Price-to-Earnings Ratio (TTM)
REGN
13.68
Biotechnology Industry
- Max
- 60.14
- Q3
- 38.17
- Median
- 29.01
- Q1
- 15.12
- Min
- 0.00
In the lower quartile for the Biotechnology industry, REGN’s P/E Ratio of 13.68 suggests the stock may be undervalued compared to its peers, potentially presenting an attractive entry point for investors.
SYK
51.43
Health Care Equipment & Supplies Industry
- Max
- 73.48
- Q3
- 51.69
- Median
- 34.31
- Q1
- 25.74
- Min
- 11.47
SYK’s P/E Ratio of 51.43 is within the middle range for the Health Care Equipment & Supplies industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
Price-to-Sales Ratio (TTM)
REGN
4.29
Biotechnology Industry
- Max
- 76.98
- Q3
- 36.53
- Median
- 9.49
- Q1
- 4.49
- Min
- 0.00
In the lower quartile for the Biotechnology industry, REGN’s P/S Ratio of 4.29 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.
SYK
6.30
Health Care Equipment & Supplies Industry
- Max
- 9.53
- Q3
- 5.26
- Median
- 3.39
- Q1
- 2.13
- Min
- 0.00
SYK’s P/S Ratio of 6.30 is in the upper echelon for the Health Care Equipment & Supplies industry. This means the company is valued richly on its revenue stream compared to its peers, suggesting the stock is priced for a high level of future performance.
Price-to-Book Ratio (MRQ)
REGN
1.89
Biotechnology Industry
- Max
- 20.53
- Q3
- 9.76
- Median
- 4.77
- Q1
- 2.49
- Min
- 0.59
REGN’s P/B Ratio of 1.89 is in the lower quartile for the Biotechnology industry. From a value investing perspective, this is favorable, as it suggests the stock is trading at a discount to its net asset value and may offer a greater margin of safety.
SYK
7.13
Health Care Equipment & Supplies Industry
- Max
- 10.85
- Q3
- 5.98
- Median
- 3.48
- Q1
- 2.43
- Min
- 0.69
SYK’s P/B Ratio of 7.13 is in the upper tier for the Health Care Equipment & Supplies industry. This indicates that investors are paying a premium relative to the company’s net assets, a valuation that hinges on its ability to generate superior profits.
Valuation at a Glance
| Symbol | REGN | SYK |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 13.68 | 51.43 |
| Price-to-Sales Ratio (TTM) | 4.29 | 6.30 |
| Price-to-Book Ratio (MRQ) | 1.89 | 7.13 |
| Price-to-Free Cash Flow Ratio (TTM) | 17.16 | 37.29 |